[625,000% Gain] – Are You Ready for the Next Altcoin Boom?

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

A. Davis Biography and Net Worth

CFO of Verrica Pharmaceuticals

Brian Davis serves as Chief Financial Officer of the Company. Prior to joining our company, Mr. Davis, was the Chief Financial Officer of Strongbridge Biopharma plc, a public commercial-stage biopharmaceutical company, from March 2015 to September 2019. Prior to joining Strongbridge, Mr. Davis served as Senior Vice President and Chief Financial Officer at Tengion, Inc., a publicly traded regenerative medicine company, from 2010 to 2014. In 2014, Tengion, Inc. filed a petition for relief under Chapter 7 of Title 11 of the United States Bankruptcy Code. From 2009 to 2010, Mr. Davis served in a consulting capacity as Chief Financial Officer of Neose Technologies, Inc., a biopharmaceutical company. Mr. Davis worked at Neose Technologies, Inc. from 1994 to 2009, where he held several positions of increasing responsibility, including Senior Vice President and Chief Financial Officer. Mr. Davis is licensed as a certified public accountant and received a B.S. in accounting from Trenton State College and an M.B.A. from The Wharton School at the University of Pennsylvania.

What is A. Brian Davis' net worth?: The estimated net worth of A. Brian Davis is at least $11,455.20 as of June 4th, 2021. Mr. Davis owns 12,900 shares of Verrica Pharmaceuticals stock worth more than $11,455 as of November 21st. This net worth approximation does not reflect any other assets that Mr. Davis may own. Learn More about A. Brian Davis' net worth.
How do I contact A. Brian Davis?: The corporate mailing address for Mr. Davis and other Verrica Pharmaceuticals executives is 10 NORTH HIGH STREET SUITE 200, WEST CHESTER PA, 19380. Verrica Pharmaceuticals can also be reached via phone at (434) 453-3300 and via email at [email protected]. Learn More on A. Brian Davis' contact information.
Has A. Brian Davis been buying or selling shares of Verrica Pharmaceuticals?: A. Brian Davis has not been actively trading shares of Verrica Pharmaceuticals during the last ninety days. Most recently, on Friday, June 4th, A Brian Davis bought 5,000 shares of Verrica Pharmaceuticals stock. The stock was acquired at an average cost of $9.89 per share, with a total value of $49,450.00. Following the completion of the transaction, the chief financial officer now directly owns 12,900 shares of the company's stock, valued at $127,581. Learn More on A. Brian Davis' trading history.
Who are Verrica Pharmaceuticals' active insiders?: Verrica Pharmaceuticals' insider roster includes Matt Davidson (Major Shareholder), A. Davis (CFO), Christopher Hayes (Insider), Paul Manning (Director), and Ted White (CEO). Learn More on Verrica Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Verrica Pharmaceuticals?: During the last year, Verrica Pharmaceuticals insiders bought shares 5 times. They purchased a total of 1,337,691 shares worth more than $7,938,546.19. During the last year, insiders at the sold shares 2 times. They sold a total of 57,930 shares worth more than $408,985.80. The most recent insider tranaction occured on July, 22nd when CEO Ted White sold 32,469 shares worth more than $229,231.14. Insiders at Verrica Pharmaceuticals own 42.6% of the company. Learn More about insider trades at Verrica Pharmaceuticals.
Information on this page was last updated on 7/22/2024.

A. Brian Davis Insider Trading History at Verrica Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/4/2021	Buy	5,000	$9.89	$49,450.00	12,900
8/13/2020	Buy	7,900	$6.24	$49,296.00	7,900

A. Brian Davis Buying and Selling Activity at Verrica Pharmaceuticals

Verrica Pharmaceuticals Company Overview

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

Today's Range

Now: $0.87

$0.85

$0.90

50 Day Range

MA: $1.39

$0.70

$1.97

2 Week Range

Now: $0.87

$0.70

$11.41

Volume

70,057 shs

Average Volume

464,130 shs

Market Capitalization

$39.85 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.45